Start: February 26, 2021
End: March 2024
Enrollment: 40
This Phase 2 study will evaluate the effectiveness of cannabidiol (CBD) oil to reduce agitation in people with Alzheimer's disease and lessen caregiver burden. Participants will be randomly assigned to take a capsule of CBD oil or placebo twice a day for six weeks and complete questionnaires during the 15-week study. Researchers will evaluate changes in agitation, aggression, and quality of life for the person with dementia, as well as caregiver burden. Researchers will also assess changes in other behavioral and psychological symptoms of dementia, cognitive function, and sleep quality.
Minimum Age: 50 Years
Maximum Age: 90 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Virginia | |
---|---|
Eastern Virginia Medical School
Norfolk, VA 23510
Recruiting
Hamid Okhravi, MD |
Lead: Eastern Virginia Medical School
Collaborator Sponsor
Source: ClinicalTrials.gov ID: NCT04436081
An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health